Smith was tapped as Viatris’s CEO for his clinical development and commercialization expertise.
Smith has strategic acumen and commercial expertise, combined with vast experience in new product development, including clinical approach and regulatory interactions, M&A, and global operations.
He will execute the Viatris strategy, balancing a targeted portfolio of complex generic and branded medicines while funding the development and launch of new drugs.
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.